Patent details

EP4076398 Title: LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-PEF)

Basic Information

Publication number:
EP4076398
PCT Application Number:
US2020065166
Type:
European Patent Granted for LU
Legal Status:
In force
Application number:
EP209008481
PCT Publication Number:
WO2021126884
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-PEF)
French Title of Invention:
LEVOSIMENDAN POUR TRAITER L'HYPERTENSION PULMONAIRE ACCOMPAGNÉE D'UNE INSUFFISANCE CARDIAQUE AU MOYEN D'UNE FRACTION D'ÉJECTION PRÉSERVÉE (PH-HF-PEF)
German Title of Invention:
LEVOSIMENDAN ZUM BEHANDELN DER PULMONALEN HYPERTENSION BEI HERZINSUFFIZIENZ MIT ERHALTENER AUSWURFFRAKTION (PH-HF-PEF)
SPC Number:

Dates

Filing date:
15/12/2020
Grant date:
18/02/2026
EP Publication Date:
26/10/2022
PCT Publication Date:
24/06/2021
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
18/02/2026
EP B1 Publication Date:
18/02/2026
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
15/12/2040
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
11/02/2026
 
 

Name:
Tenax Therapeutics, Inc.
Address:
One Copley Parkway, Suite 490, Morrisville, NC 27560, United States (US)

Inventor

1

Name:
RICH, Stuart
Address:
United States (US)

2

Name:
HAY, Douglas
Address:
United States (US)

3

Name:
RANDALL, Douglas
Address:
United States (US)

Priority

1

Priority Number:
201962948735 P
Priority Date:
16/12/2019
Priority Country:
United States (US)

2

Priority Number:
202062967920 P
Priority Date:
30/01/2020
Priority Country:
United States (US)

3

Priority Number:
202062988720 P
Priority Date:
12/03/2020
Priority Country:
United States (US)

4

Priority Number:
202063033773 P
Priority Date:
02/06/2020
Priority Country:
United States (US)

5

Priority Number:
202063064671 P
Priority Date:
12/08/2020
Priority Country:
United States (US)

Classification

IPC classification:
A61K 31/216; A61K 9/08; A61K 31/41; A61K 31/495; A61K 31/50; A61P 9/04; A61P 9/12; A61K 9/00;

Publication

European Patent Bulletin

1

Issue number:
202608
Publication date:
18/02/2026
Description:
Grant (B1)

2

Issue number:
202613
Publication date:
25/03/2026
Description:
Application number/publication number of the divisional application (Art. 76) changed

Annual Fees

Annual Fee Due Date:
31/12/2026
Annual Fee Number:
7
Annual Fee Amount:
82 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages